Archer DX

FusionPlex

Solid Tumor


The Archer® FusionPlex Solid Tumor panel is a robust targeted sequencing assay to simultaneously detect and identify fusions and other mutations associated with over 50 genes linked to various carcinomas. This panel uses Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment to detect all fusions associated with the genes in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.

Read More »
Pan-Heme


The Archer® FusionPlex Pan-Heme panel is an Anchored Multiplex PCR (AMP™)-based next-generation sequencing (NGS) test to detect and identify fusions, point mutations and expression levels from ribonucleic acid (RNA) input. The panel encompasses all targets in the FusionPlex heme panels, amounting to over 199 genes relating to lymphoid and myeloid malignancies. By using gene-specific primers to amplify into molecular barcodes ligated onto the cDNA fragment ends, both known and novel fusions can be identified.

Read More »
Lymphoma


The Archer® FusionPlex Lymphoma panel is a targeted next-generation sequencing (NGS) test to simultaneously detect and identify fusions, point mutations, and expression levels in 125 genes linked to lymphomas. Using Anchored Multiplex PCR (AMP™)-based enrichment, fusions can be identified even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression detection and coverage over key hotspot regions.

Read More »
Myeloid


The Archer® FusionPlex Myeloid panel is a targeted next-generation sequencing (NGS) test to detect and identify fusions, point mutations and expression levels from 84 genes associated with myeloid-origin malignancies. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.

Read More »
Acute Lymphoblastic Leukemia (ALL)


The Archer® FusionPlex Acute Lymphoblastic Leukemia (ALL) panel is a targeted next-generation sequencing (NGS) test to detect and identify fusions, point mutations and expression levels in 81 genes associated with Acute Lymphoblastic Leukemia, including all recurrent Ph-like ALL fusion events. The panel uses Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment to detect fusions of all target genes in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.

Read More »
Heme v2


The Archer® FusionPlex Heme v2 panel is an ribonucleic acid (RNA)-based targeted sequencing test that detects and identifies fusions of 87 genes associated with hematological malignancies. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. Additionally, select genes are targeted for molecular barcode-enabled relative expression level detection and point mutation coverage.

Read More »
Lung


The Archer® FusionPlex Lung panel is a targeted next-generation sequencing (NGS) test to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.

Read More »
Comprehensive Thyroid & Lung


The Archer® FusionPlex Comprehensive Thyroid and Lung (CTL) panel is a targeted next-generation sequencing (NGS) panel to detect gene fusions, single-nucleotide variant (SNV), indels, splicing and gene expression in 36 genes associated with lung and thyroid cancers. This panel complements the Archer VariantPlex® CTL panel for comprehensive mutation profiling of fusions, copy number variations (CNVs) and variants.

Read More »
ALK RET ROS1 v2


The Archer® FusionPlex ALK, RET, ROS1 v2 panel is a targeted sequencing test to simultaneously detect and identify fusions and mutations of human ALK, RET and ROS1 genes. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions of all genes in a single sequencing test, even without prior knowledge of fusion partners or breakpoints. The panel also detects select insertions and point mutations in ALK and RET, including those reported in cell-based tests to convey crizotinib resistance.

Read More »
Oncology Research


The Archer® FusionPlex Oncology Research panel is a targeted next-generation sequencing (NGS) test to simultaneously detect and identify fusions and other mutations associated with 74 genes found in ribonucleic acid (RNA) transcripts that are linked to various cancers. This panel is extensive and purpose-built to advance fusion discovery, including research efforts in the area of Ph-like acute lymphoblastic leukemia (ALL) fusions.

Read More »

You are now leaving archerdx.com. Links to sites outside of ArcherDX are provided as a resource to the viewer. ArcherDX accepts no responsibility for the content of linked sites. 

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.